Cutler Group LP Arbutus Biopharma Corp Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$1.88 - $2.88 $940 - $1,440	-500 Reduced 71.43%	200 $0
Q2 2022 Aug 04, 2022	SELL	$1.98 - $3.17 $5,346 - $8,559	-2,700 Reduced 79.41%	700 $0
Q1 2022 Apr 14, 2022	SELL	$2.42 - $3.98 $64,614 - $106,266	-26,700 Reduced 88.7%	3,400 $0
Q4 2021 Jan 18, 2022	BUY	$3.11 - $4.61 $90,190 - $133,690	29,000 Added 2636.36%	30,100 $5,000
Q3 2021 Oct 26, 2021	SELL	$2.65 - $4.62 $42,930 - $74,844	-16,200 Reduced 93.64%	1,100 $0

Q3 2020 Oct 27, 2020	BUY	$1.75 - $6.2 $30,275 - $107,260	17,300 New	17,300 $4,000
Q2 2019 Aug 09, 2019	SELL	$1.46 - $4.44 $8,760 - $26,640	-6,000 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$3.41 - $4.57 $6,820 - $9,140	-2,000 Reduced 25.0%	6,000 $3,000
Q3 2018 Nov 07, 2018	BUY	$7.85 - $12.35 $46,315 - $72,865	5,900 Added 280.95%	8,000 $20,000
Q3 2017 Oct 17, 2017	BUY	$3.4 - $7.0 $7,140 - $14,700	2,100	2,100 $0

130

82.1M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $553M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.